Large‐scale studies are needed to explore the complete molecular profile of gastric adenocarcinoma, confirm the prognostic significance of TCGA classification and ARID1A negative expression, and ultimately achieve risk stratification and more individualized patient management. The gene discussed is ARID1A; the disease is gastric adenocarcinoma.